Nurix Therapeutics, Inc.
NASDAQ:NRIX
25.04 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Nurix Therapeutics, Inc. |
Symbool | NRIX |
Munteenheid | USD |
Prijs | 25.04 |
Beurswaarde | 1,773,740,952 |
Dividendpercentage | 0% |
52-weken bereik | 4.96 - 27.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Website | https://www.nurixtx.com |
An error occurred while fetching data.
Over Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)